A New Era in Prostate Cancer Treatment? Understanding DNA Repair Deficiencies and the Therapeutic Rationale for PARP Inhibition
Advanced Renal Cell Carcinoma: Patient-Specific Recommendations from an International Panel of Experts
Overview of DNA Repair Deficiency in Advanced Prostate Cancer
DNA Repair Defects as a Therapeutic Target in Advanced Prostate Cancer: The Role of PARP Inhibitors
The Intersection of Germline and Somatic Genetic Testing in Advanced Prostate Cancer
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.